Cited by 159Protein Tyrosine PhosphatasesImmunodeficiency and Autoimmune DisordersAutoimmune and Inflammatory Disorders Research

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor

Open access

Chan, Rebecca J., Leedy, Melissa B., Munugalavadla, Veerendra, Voorhorst, Cara S., Li, Yanjun, Yu, Menggang, Kapur, Reuben·2005·Blood

DOI 10.1182/blood-2004-10-4002PMC PMC1895012

Open this paper in CoChat — free account

Abstract

Juvenile myelomonocytic leukemia (JMML) is a lethal disease of young children characterized by hypersensitivity of hematopoietic progenitors to granulocyte-macrophage colony-stimulating factor (GM-CSF). Mutations in PTPN11, which encodes the protein tyrosine phosphatase Shp-2, are common in JMML. We hypothesized that PTPN11 mutations induce hypersensitivity of hematopoietic progenitors to GM-CSF and confer increased GM-CSF–stimulated phospho–extracellular signal-regulated kinase (Erk) levels. To test this hypothesis, the wild-type (WT) and 3 mutant Ptpn11 cDNAs (E76K, D61V, and D61Y) were transduced into murine bone marrow cells to examine GM-CSF–stimulated granulocyte-macrophage colony-forming unit (CFU-GM) growth, macrophage progenitor proliferation, and activation of the Ras signaling pathway. Expression of the Shp-2 mutants induced progenitor cell hypersensitivity to GM-CSF compared with cells transduced with vector alone or WT Shp-2. Macrophage progenitors expressing the Shp-2 mutants displayed both basal and GM-CSF–stimulated hyperproliferation compared with cells transduced with vector alone or WT Shp-2. Consistently, macrophage progenitors transduced with the Shp-2 mutants demonstrated constitutively elevated phospho-Erk levels and sustained activation of phospho-Erk following GM-CSF stimulation compared with vector alone or WT Shp-2. These data support the hypothesis that PTPN11 mutations induce hematopoietic progenitor hypersensitivity to GM-CSF due to hyperactivation of the Ras signaling axis and provide a basis for the GM-CSF signaling pathway as a target for rational drug design in JMML.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2004-10-4002

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R. B., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,736
STATs: Signal Transducers and Activators of Transcription
Ihle, J. N. (1996) · Cell · doi:10.1016/s0092-8674(00)81277-5 · Cited by 1,381
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe‐Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 997
PTPN11 Mutations in Noonan Syndrome: Molecular Spectrum, Genotype-Phenotype Correlation, and Phenotypic Heterogeneity
Tartaglia, M., Kalidas, K., Shaw, A. C., Song, X., Musat, D. L., van der Burgt, I., Brunner, H. G., Bertola, D. R., Crosby, A. H., Ion, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340847 · Cited by 801
SH2-Containing Phosphotyrosine Phosphatase as a Target of Protein-Tyrosine Kinases
Feng, G., Hui, C., & Pawson, T. J. (1993) · Science · doi:10.1126/science.8096088 · Cited by 663
Suppression of SHP-2 and ERK Signalling Promotes Self-Renewal of Mouse Embryonic Stem Cells
Burdon, T., Stracey, C., Chambers, I., Nichols, J., & Smith, A. G. (1999) · Developmental Biology · doi:10.1006/dbio.1999.9265 · Cited by 585
Loss of The Normal NF1 Allele from the Bone Marrow of Children with Type 1 Neurofibromatosis and Malignant Myeloid Disorders
Shannon, K., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P. A., & McCormick, F. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 440
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2003) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 422
Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation
Araki, T., Mohi, G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 419

Show all 40 references

Research works printed but not linked: 1

Mongomery DC. Design and Analysis of Experiments. 4th ed. Hoboken, NJ: John Wiley & Sons; 1997.

Sorted by citations

Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,712
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Protein-tyrosine phosphatases and cancer
Östman, A., Hellberg, C. B., & Böhmer, F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1837 · Cited by 665
Noonan syndrome and clinically related disorders
Tartaglia, M., Gelb, B. D., & Zenker, M. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.09.002 · Cited by 432
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 392
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G. (2006) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 378
Self-citation
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 340
Protein tyrosine phosphatases as potential therapeutic targets
He, R., Yu, Z.-H., Zhang, R., & Zhang, Z. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.80 · Cited by 336
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in bioscience · doi:10.2741/3051 · Cited by 314
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum
Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., Scioletti, A. P., Esposito, G., Cordeddu, V., Lepri, F., et al. (2009) · Human Mutation · doi:10.1002/humu.20955 · Cited by 303
Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor
Chen, L., Sung, S., Yip, M. L. R., Lawrence, H. R., Ren, Y., Guida, W. C., Sebti, S. M., Lawrence, N. J., & Wu, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025536 · Cited by 280
The Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277
The role of Shp2 (PTPN11) in cancer
Mohi, G., & Neel, B. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.011 · Cited by 282
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
Kratz, C. P. (2005) · Blood · doi:10.1182/blood-2005-02-0531 · Cited by 266
Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis
Tartaglia, M., Zampino, G., & Gelb, B. D. (2010) · Molecular Syndromology · doi:10.1159/000276766 · Cited by 256
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome Phenotype
Carta, C., Pantaleoni, F., Bocchinfuso, G., Stella, L., Vasta, I., Sárközy, A., Digilio, C., Palleschi, A., Pizzuti, A., Grammatico, P., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/504394 · Cited by 225
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Yuan, X., Bu, H., Zhou, J., Yang, C., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 221
A role for the scaffolding adapter GAB2 in breast cancer
Bentires‐Alj, M., Gil, S. G., Chan, R., Wang, Z. C., Wang, Y., Imanaka, N., Harris, L. N., Richardson, A. L., Neel, B. G., & Gu, H. (2005) · Nature Medicine · doi:10.1038/nm1341 · Cited by 212
Self-citation
Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
Zhang, X., He, Y., Liu, S., Yu, Z.-H., Jiang, Z., Yang, Z., Dong, Y., Nabinger, S. C., Wu, L., Gunawan, A. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901645u · Cited by 203
Self-citation
Disorders of dysregulated signal traffic through the RAS‐MAPK pathway: phenotypic spectrum and molecular mechanisms
Tartaglia, M., & Gelb, B. D. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05790.x · Cited by 201
Protein Tyrosine Phosphatases: Structure, Function, and Implication in Human Disease
Tautz, L., Critton, D., & Grotegut, S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-562-0_13 · Cited by 167
Oncogenes in Myeloproliferative Disorders
Tefferi, A., & Gilliland, D. G. (2007) · Cell Cycle · doi:10.4161/cc.6.5.3919 · Cited by 160
Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia
Loh, M. L. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08525.x · Cited by 159
Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Scott, L. M., Lawrence, H. R., Sebti, S. M., Lawrence, N. J., & Wu, J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209027 · Cited by 162
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Schubbert, S., Lieuw, K. H., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., & Shannon, K. (2005) · Blood · doi:10.1182/blood-2004-11-4207 · Cited by 148
Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options
Niemeyer, C. M., & Kratz, C. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06958.x · Cited by 148
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials
Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
Gandre-Babbe, S., Paluru, P. C., Aribeana, C. N., Chou, S. T., Bresolin, S., Lu, L., Sullivan, S., Tasian, S., Weng, J. M., Favre, H., et al. (2011) · Blood · doi:10.1182/blood-2013-01-478412 · Cited by 109
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
Chan, G., Kalaitzidis, D., Usenko, T. S., Kutok, J. L., Yang, W., Mohi, G., & Neel, B. G. (2009) · Blood · doi:10.1182/blood-2008-10-182626 · Cited by 121
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia
Xu, R., Yu, Y., Zheng, S. S., Zhao, X., Dong, Q., He, Z., Liang, Y., Lu, Q., Fang, Y., Gan, X., et al. (2005) · Blood · doi:10.1182/blood-2004-10-4057 · Cited by 121
Deregulated Ras signaling in developmental disorders: new tricks for an old dog
Schubbert, S., Bollag, G. E., & Shannon, K. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.004 · Cited by 117
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia
Muramatsu, H., Makishima, H., Jankowska, A. M., Cazzolli, H., O’Keefe, C. L., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., et al. (2009) · Blood · doi:10.1182/blood-2009-06-226340 · Cited by 115
Non–lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells
Xu, D., Liu, X., Yu, W., Meyerson, H. J., Guo, C., Gerson, S. L., & Qu, C. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110450 · Cited by 115
Tyrosine phosphatase SHP-2 mediates C-type lectin receptor–induced activation of the kinase Syk and anti-fungal TH17 responses
Deng, Z., Ma, S., Zhou, H., Zang, A., Fang, Y., Li, T., Shi, H., Liu, M., Du, M., Taylor, P. R., et al. (2015) · Nature Immunology · doi:10.1038/ni.3155 · Cited by 117
The molecular genetics of RASopathies : An update on novel disease genes and new disorders
Tartaglia, M., Aoki, Y., & Gelb, B. D. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32012 · Cited by 103
Biochemical and Functional Characterization of Germ Line KRAS Mutations
Schubbert, S., Bollag, G. E., Lyubynska, N., Nguyen, H. T., Kratz, C. P., Zenker, M., Niemeyer, C. M., Molven, A., & Shannon, K. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00965-07 · Cited by 99
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Loriaux, M., Levine, R. L., Tyner, J. W., Fröhling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101394 · Cited by 92
Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation
Verbrugge, A., Ruiter, T. E.-D., Geest, C. R., Coffer, P. J., & Meyaard, L. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705370 · Cited by 90
Crossing paths: interactions between the cell death machinery and growth factor survival signals
Brumatti, G., Salmanidis, M., & Ekert, P. G. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0288-8 · Cited by 85
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia
Mulero‐Navarro, S., Sevilla, A., Román, Á., Lee, D., D’Souza, S. L., Pardo, S., Riess, I., Su, J., Cohen, N., Schaniel, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.019 · Cited by 83
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal
Heuser, M., Sly, L. M., Argiropoulos, B., Kuchenbauer, F. C., Lai, C. K., Weng, A. P., Leung, M., Lin, G., Brookes, C., Fung, S., et al. (2009) · Blood · doi:10.1182/blood-2009-06-227603 · Cited by 80
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 ( PTPN11 )
Liu, W., Yu, B., Xu, G., Xu, W.-R., Loh, M. L., Li-da, T., & Qu, C. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400474r · Cited by 76
Somatic PTPN11 mutations in childhood acute myeloid leukaemia
Tartaglia, M., Martinelli, S., Iavarone, I., Cazzaniga, G., Spinelli, M., Giarin, E., Petrangeli, V., Carta, C., Masetti, R., Aricò, M., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05457.x · Cited by 76
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Huang, W.-Q., Lin, Q., Zhuang, X., Cai, L., Ruan, R., Lu, Z., & Tzeng, C. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140717105001 · Cited by 70
Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells
Xu, D., Wang, S., Yu, W., Chan, G., Araki, T., Bunting, K. D., Neel, B. G., & Qu, C. (2010) · Blood · doi:10.1182/blood-2010-01-265652 · Cited by 69
Negative Regulation of Stat3 by Activating PTPN11 Mutants Contributes to the Pathogenesis of Noonan Syndrome and Juvenile Myelomonocytic Leukemia
Zhang, W., Chan, R. J., Chen, H., Yang, Z., He, Y., Zhang, X., Luo, Y., Yin, F., Moh, A., Miller, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.020495 · Cited by 63
Self-citation
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition
Chen, L., Chen, W., Mysliwski, M., Serio, J., Ropa, J. P., Abulwerdi, F. A., Chan, R. J., Patel, J. P., Tallman, M. S., Paietta, E. M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.18 · Cited by 61
Self-citation
SHP2 forecast for the immune system: fog gradually clearing
Salmond, R. J., & Alexander, D. R. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.01.007 · Cited by 63
Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders
Kratz, C. P., Schubbert, S., Bollag, G. E., Niemeyer, C. M., Shannon, K., & Zenker, M. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3128 · Cited by 59
PU.1, Interferon Regulatory Factor (IRF) 2, and the Interferon Consensus Sequence-binding Protein (ICSBP/IRF8) Cooperate to Activate NF1 Transcription in Differentiating Myeloid Cells
Huang, W., Horvath, E., & Eklund, E. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607760200 · Cited by 58
An unexpected new role of mutant Ras: perturbation of human embryonic development
Kratz, C. P., Niemeyer, C. M., & Zenker, M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0135-4 · Cited by 57
The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo
Nabinger, S. C., Li, X. J., Ramdas, B., He, Y., Zhang, X., Zeng, L., Richine, B. M., Bowling, J. D., Fukuda, S., Goenka, S., et al. (2012) · Leukemia · doi:10.1038/leu.2012.308 · Cited by 56
Self-citation
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Niogret, C., Birchmeier, W., & Guarda, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02468 · Cited by 58
Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia
Koike, K., & Matsuda, K. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07104.x · Cited by 55
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors
Martinelli, S., Carta, C., Flex, E., Binni, F., Cordisco, E. L., Moretti, S., Puxeddu, E., Tonacchera, M., Pinchera, A., McDowell, H. P., et al. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.10.003 · Cited by 52
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling
Yu, W., Daino, H., Chen, J., Bunting, K. D., & Qu, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507622200 · Cited by 51
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations
Liu, W., Yu, W.-M., Zhang, J., Chan, R. J., Loh, M. L., Zhang, Z., Bunting, K. D., & Qu, C.-K. (2016) · Leukemia · doi:10.1038/leu.2016.326 · Cited by 51
Self-citation
A critical role for SHP2 in STAT5 activation and growth factor–mediated proliferation, survival, and differentiation of human CD34+ cells
Li, L., Modi, H., McDonald, T., Rossi, J., Yee, J., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-06-288910 · Cited by 49
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11 -Associated Malignancies
Yu, B., Liu, W., Yu, W., Loh, M. L., Alter, S. P., Guvench, O., MacKerell, A. D., Li-da, T., & Qu, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0049-t · Cited by 48
Induction of a Tumor-associated Activating Mutation in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhances Mitochondrial Metabolism, Leading to Oxidative Stress and Senescence
Zheng, H., Li, S., Hsu, P., & Qu, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.462291 · Cited by 48
How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?
Édouard, T., Montagner, A., Dance, M., Conte-Auriol, F., Yart, A., Parfait, B., Tauber, M., Salles, J., & Raynal, P. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6509-0 · Cited by 48
Noonan Syndrome-associated SHP-2/Ptpn11 Mutants Enhance SIRPα and PZR Tyrosyl Phosphorylation and Promote Adhesion-mediated ERK Activation
Eminaga, S., & Bennett, A. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801382200 · Cited by 46
SHP2 Is a Target of the Immunosuppressant Tautomycetin
Liu, S., Yu, Z.-H., Yu, X., Huang, S., Luo, Y., Wu, L., Shen, W., Yang, Z., Wang, L., Gunawan, A. M., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.10.015 · Cited by 44
Self-citation
SHP2E76K mutant promotes lung tumorigenesis in transgenic mice
Schneeberger, V. E., Luetteke, N., Ren, Y., Berns, H., Chen, L., Foroutan, P., Martinez, G. V., Haura, E. B., Chen, J., Coppola, D., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu025 · Cited by 44
Identification of Small Molecular Weight Inhibitors of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 (SHP-2) via in Silico Database Screening Combined with Experimental Assay
Yu, W., Guvench, O., MacKerell, A. D., & Qu, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800229d · Cited by 43
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
Chen, J., Yu, W., Daino, H., Broxmeyer, H. E., Druker, B. J., & Qu, C. (2006) · Blood · doi:10.1182/blood-2006-04-019141 · Cited by 42
Leukemia-Associated, Constitutively Active Mutants of SHP2 Protein Tyrosine Phosphatase Inhibit NF1 Transcriptional Activation by the Interferon Consensus Sequence Binding Protein
Huang, W., Saberwal, G., Horvath, E., Zhu, C., Lindsey, S., & Eklund, E. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00036-06 · Cited by 41
Protein-tyrosine Phosphatase Shp2 Positively Regulates Macrophage Oxidative Burst
Li, X. J., Goodwin, C. B., Nabinger, S. C., Richine, B. M., Yang, Z., Hanenberg, H., Ohnishi, H., Matozaki, T., Feng, G., & Chan, R. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.614057 · Cited by 43
Self-citation
Structure-Based Kinetic Models of Modular Signaling Protein Function: Focus on Shp2
Barua, D., Faeder, J. R., & Haugh, J. M. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.093484 · Cited by 41
Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival
Yang, Z., Li, Y., Yin, F., & Chan, R. J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.04.016 · Cited by 41
Self-citation
Counteracting Effects Operating on Src Homology 2 Domain-containing Protein-tyrosine Phosphatase 2 (SHP2) Function Drive Selection of the Recurrent Y62D and Y63C Substitutions in Noonan Syndrome*
Martinelli, S., Nardozza, A. P., Vigne, S. D., Sabetta, G., Torreri, P., Bocchinfuso, G., Flex, E., Venanzi, S., Palleschi, A., Gelb, B. D., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.350231 · Cited by 38
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
Goodwin, C. B., Li, X.-J., Mali, R., Chan, G., Kang, M. W., Liu, Z.-Y., Vanhaesebroeck, B., Neel, B., Loh, M., Lannutti, B., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535104 · Cited by 39
Self-citation
Activating Mutations in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhance Reactive Oxygen Species Production That Contributes to Myeloproliferative Disorder
Xu, D., Zheng, H., Yu, W.-M., & Qu, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063152 · Cited by 37
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Stasik, S., Eckardt, J., Krämer, M., Röllig, C., Krämer, A., Scholl, S., Hochhaus, A., Crysandt, M. M., Brümmendorf, T. H., Naumann, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004631 · Cited by 36
Protein Tyrosine Phosphatase SHP2 Mediates Chronic Insulin-Induced Endothelial Inflammation
Giri, H., Muthuramu, I., Dhar, M., Rathnakumar, K., Ram, U., & Dixit, M. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.239251 · Cited by 37
Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia
Loh, M. L. (2010) · Hematology · doi:10.1182/asheducation-2010.1.357 · Cited by 37
Noonan Syndrome/Leukemia-associated Gain-of-function Mutations in SHP-2 Phosphatase (PTPN11) Enhance Cell Migration and Angiogenesis
Wang, S., Yu, W., Zhang, W., McCrae, K. R., Neel, B. G., & Qu, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804129200 · Cited by 37
p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes
Anur, P., Yates, J. E., Garbati, M. R., Vanderwerf, S. M., Keeble, W. W., Rathbun, K. R., Hays, L. E., Tyner, J. W., Svahn, J., Cappelli, E., et al. (2012) · Blood · doi:10.1182/blood-2011-06-354647 · Cited by 36
SH2 Domain-Containing Protein-Tyrosine Phosphatases
Neel, B. G., Chan, G., & Dhanji, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00098-x · Cited by 34
Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal
Chan, R. J., Li, Y., Hass, M. N., Walter, A., Voorhorst, C. S., Shelley, W. C., Yang, Z., Orschell, C. M., & Yöder, M. C. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.04.017 · Cited by 32
Self-citation
Gain‐of‐function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs
Thaiwong, T., Sirivisoot, S., Takada, M., Yuzbasiyan‐Gurkan, V., & Kiupel, M. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12357 · Cited by 32
Targeting SHP2 phosphatase in hematological malignancies
Kanumuri, R., Pasupuleti, S. K., Burns, S. S., Ramdas, B., & Kapur, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066518 · Cited by 31
Self-citation
Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating PTPN11 Mutants
Yang, Z., Kondo, T., Voorhorst, C. S., Nabinger, S. C., Ndong, L., Yin, F., Chan, E. M., Yu, M., Würstlin, O., Kratz, C. P., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01330-08 · Cited by 32
Self-citation
Noonan Syndrome, the Ras–MAPK Signalling Pathway and Short Stature
Binder, G. (2009) · Hormone Research in Paediatrics · doi:10.1159/000192439 · Cited by 29
Structural and functional effects of disease‐causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP‐2
Bocchinfuso, G., Stella, L., Martinelli, S., Flex, E., Carta, C., Pantaleoni, F., Pispisa, B., Venanzi, M., Tartaglia, M., & Palleschi, A. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21050 · Cited by 29
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML)
Geissler, K. H., Jäger, E., Barna, A., Gurbisz, M., Marschon, R., Graf, T., Graf, E., Borjan, B., Jilch, R., Geissler, C., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1526-1 · Cited by 28
Angiopoietin‐2 mediates thrombin‐induced monocyte adhesion and endothelial permeability
Rathnakumar, K., Savant, S., Giri, H., Ghosh, A., Fisslthaler, B., Fleming, I., Ram, U., Bera, A. K., Augustin, H. G., & Dixit, M. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13376 · Cited by 27
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia
Locatelli, F., Algeri, M., Merli, P., & Strocchio, L. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1421937 · Cited by 27
LST1/A Is a Myeloid Leukocyte-specific Transmembrane Adaptor Protein Recruiting Protein Tyrosine Phosphatases SHP-1 and SHP-2 to the Plasma Membrane
Dráber, P., Štěpánek, O., Hrdinka, M., Drobek, A., Chmátal, L., Mala, L., Ormsby, T., Angelisová, P., Hořejšı́, V., & Brdička, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.339143 · Cited by 24
Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway
Bunda, S., Qin, K., Kommaraju, K., Heir, P., & Ohh, M. (2014) · Oncogene · doi:10.1038/onc.2013.596 · Cited by 22
A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma
Hu, Z., Wang, X., Fang, H., Liu, Y., Chen, D., Zhang, Q., Liu, X., Wei, D., Qu, C., & Wang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6561 · Cited by 23
After 95 years, it's time to eRASe JMML
Meynier, S., & Rieux‐Laucat, F. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100652 · Cited by 23
SHP-2 tyrosine phosphatase in human diseases.
Zheng, H., Alter, S. P., & Qu, C. (2009) · PubMed Central · Cited by 20
Genetic disruption of the PI3K regulatory subunits, p85 , p55 , and p50 , normalizes mutant PTPN11-induced hypersensitivity to GM-CSF
Goodwin, C. B., Yang, Z., Yin, F., Yu, M., & Chan, R. J. (2012) · Haematologica · doi:10.3324/haematol.2011.046896 · Cited by 19
Self-citation
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients
Geissler, K. H., Jäger, E., Barna, A., Gurbisz, M., Graf, T., Graf, E., Nösslinger, T., Pfeilstöcker, M., Tüchler, H., Sliwa, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083025 · Cited by 19

Authors: Chan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., & Kapur, R.
Affiliations: Indiana University Indianapolis (US)
ORCID: Chan, Rebecca J.
Munugalavadla, Veerendra
Yu, Menggang
Kapur, Reuben
Venue: Blood
Publisher: American Society of Hematology
Published: 2005-05-01
Volume: 105
Issue: 9
Pages: 3737-3742
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2004-10-4002
PMC: PMC1895012
OpenAlex: W1983831457
Cited by: 156
References: 40
Citations by year: 2026: 2 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 9
FWCI: 6.27
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Heart, Lung, and Blood Institute (R01HL075816)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords: juvenile myelomonocytic leukemia, PTPN11 mutation, SHP2, GM-CSF, GM-CSF hypersensitivity, hematopoietic progenitor cells, macrophage progenitors, Ras signaling, ERK activation, CFU-GM, therapeutic target
MeSH terms: Animals, Bone Marrow Cells, Hematopoietic Stem Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Signal Transduction, Leukemia, Myelomonocytic, Chronic, Granulocyte-Macrophage Colony-Stimulating Factor, Protein Tyrosine Phosphatases, Point Mutation, ras Proteins, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks